Floatz logo

Iruplinalkib

ALK

Peking University Shenzhen HospitalActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the ALK cohort.

Asset / SponsorPhaseRating
Ensartinib
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2CCC

Same molecule, other indications

Iruplinalkib is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
IruplinalkibDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →